NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 18 of 24
Tailored Approach to Sleep Health Education: A Community Engaged Approach
NCT02507089
Adverse Health Effects of Mainstream and Secondhand Hookah Smoke in NYC Hookah Bars
NCT02638194
Pilot Study Evaluating Safety of Unilateral Gamma Knife Subthalamotomy for Parkinson's Disease
NCT02249559
Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry
NCT01999946
Metformin Prostate Cancer Adjuvant Trial
NCT02176161
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
NCT02061293
Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care
NCT01893827
Understanding the Mechanism(s) of Action on the Modified Atkins Diet for Epilepsy: Human Brain Tissues
NCT02565966
Lymph Node Assessment Using Simultaneous 18F-FDG-PET and MRI
NCT02180308
Craniomaxillofacial Allotransplantation
NCT02158793
Anti-platelet Effects of Colchicine in Healthy Volunteers
NCT02140372
Exploratory Investigation of Advanced PET/MRI Metrics for Bladder Cancer Characterization
NCT02287701
Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors
NCT02011685
Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program
NCT02024204
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NCT02129647
Vegan vs AHA Diet on Inflammation and Glucometabolic Profile in Patients With CAD
NCT02135939
Patient-Provider Communication and Medication Adherence
NCT01428011
Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients
NCT02701582
Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
NCT02608879
Platelet Activity in Vascular Surgery and Cardiovascular Events
NCT02106429
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
NCT02061449
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
NCT02075021
Impact of CRISP on Self-Efficacy, Loneliness, and Depression
NCT02030197
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
NCT01981759
PRP vs Corticosteroid in Baker's Cyst
NCT02249377
Risk Factor Control Before Orthopedic Surgery
NCT01837069
Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment
NCT02032433
Aortic Valve and Root Measurements Under Real-Time 3-Dimensional Visualization During Angiography
NCT02073617
ISCHEMIA-Chronic Kidney Disease Trial
NCT01985360
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
NCT02451696
PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer
NCT02042053
Biomarkers of Irritant-Induced and Allergic Asthma
NCT02740543
Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients
NCT02106325
World Trade Center Adolescent Health Study
NCT02068183
GATE: Generalized Anxiety - A Treatment Evaluation
NCT01912287
The Effects of Cold Liquids on the Swallowing Mechanism in Preterm Infants
NCT01863264
Direct Cortical Measurement of the Intensity and Pattern of Current Flow Produced by TDCS
NCT02263274
Efficacy of Vitamin D Therapy on Glucose Homeostasis in Obese Adolescents
NCT02414529
Effect of Intravenous Corticosteroid Injections on Dysphagia After Cervical Spine Surgery
NCT02266797
Utility of High-Fidelity Simulation In the Education and Assessment of Residents in the Recognition and Management of the Sepsis Syndrome
NCT01992120
Exemestane and Cyclophosphamide for Metastatic Breast Cancer
NCT01963481
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors
NCT02515487
Health-related Quality of Life in Rare Kidney Stone
NCT02124395
Single Shot Versus OnQ Pump in Extremity Fractures
NCT02280291
Use of PET/MRI Tracer to Further Understanding of Prostate Cancer Development
NCT02106416
Pre-oxygenation and Measures of Gas Exchanges During Seizures in the Epilepsy Monitoring Unit
NCT02241798
Strategies for Recovery of Dexterity Post Stroke
NCT01977027
Sleep, Aging and Risk for Alzheimer's Disease
NCT01962779
Investigation of the Role of Steroids in Enhancing Voice Therapy Outcomes
NCT02286960
Mobile Insulin Titration Intervention
NCT01879579
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.